Početna stranicaMPSYF • OTCMKTS
add
MorphoSys
Preth. zaklj. cijena
73,27 $
Godišnji raspon
20,15 $ - 73,27 $
Tržišna kapitalizacija
2,77 mlr. USD
P/E omjer
-
Prinos dividende
-
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Prihod | 34,64 mil. | −34,84 % |
Operativni troškovi | 78,93 mil. | −17,78 % |
Neto dohodak | −79,19 mil. | −7,07 % |
Neto profitabilnost | −228,59 | −64,30 % |
Zarada po dionici | — | — |
EBITDA | −44,38 mil. | 6,70 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 512,31 mil. | −23,74 % |
Ukupna imovina | 1,71 mlr. | −20,42 % |
Ukupne obveze | 2,04 mlr. | −3,37 % |
Ukupni kapital | −334,72 mil. | — |
Dionice u optjecaju | 37,66 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −8,24 | — |
Povrat imovine | −6,44 % | — |
Povrat kapitala | −7,90 % | — |
Tok novca
Neto promjena novca
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −79,19 mil. | −7,07 % |
Gotovina od poslovanja | −131,32 mil. | −4,25 % |
Gotovina iz ulaganja | 116,76 mil. | 402,25 % |
Gotovina iz financiranja | −2,98 mil. | 36,22 % |
Neto promjena novca | 2,41 mil. | 102,25 % |
Slobodan tok novca | 395,49 mil. | 464,18 % |
Više
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Glavni izvršni direktor
Osnovano
1992
Sjedište
Web-lokacija
Zaposlenici
446